araag2/HINT huggingface dataset:
Clinical trial NCT00809458 (phase 3, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: vitamin e
SMILES: CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C
Reason stopped: 
    low rate of accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients must have histologically or cytologically confirmed prostate cancer.

          2. Patients must have localized prostate cancer and have decided to undergo a
             prostatectomy or brachytherapy.

          3. Patient must not be taking supplemental vitamin E.

          4. Age >18 years.

          5. Life expectancy of greater than 6 months.

          6. ECOG performance status =< 2.

          7. Patients must have normal organ and marrow function as defined below:

               -  leukocytes >= 3,000/mcL

               -  absolute neutrophil count >=1,500/mcL

               -  platelets >=100,000/mcL

               -  total bilirubin within normal institutional limits

               -  AST/ALT =< 2.5 X institutional upper limit of normal

               -  creatinine =< 1.5 X normal institutional upper limit of normal

               -  INR =<1.4

               -  PTT =<1.4 X institutional upper limit of normal

          8. Patients must have the ability to understand, and the willingness to sign a written
             informed consent document.

        Exclusion Criteria:

          1. Patients who have metastatic prostate cancer.

          2. Patients may not be receiving any other investigational agents.

          3. Patients with a known bleeding diathesis or patients on therapeutic anticoagulation.
             (This does not include the use of aspirin but refers to warfarin, heparin, or low
             molecular weight heparins).

          4. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to vitamin E.

          5. The patient may not receive a gonadotrophin release agonist (such as goserelin, or
             leuprolide), or an antiandrogen (such as bicalutamide, flutamide, or nilutamide)
             during the study.

          6. Uncontrolled intercurrent illness that would limit compliance with study requirements.

               -  Inclusion of Women and Minorities

                    -  Only men are eligible for this trial. Members of all races and ethnic groups
                       are eligible for this trial.
Clinical trial NCT00328978 (phase 3, status: completed)
Conditions: schizophrenia, schizoaffective disorders
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F25.9, F25.0, F25.1, F25.8
Drugs: quetiapine
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Inclusion Criteria: Men and women, age 18-65 years with persistent positive or
             negative symptoms with a PANSS total score of ≥ 70 and < 110 and a Clinical Global
             Improvement (CGI)- Severity of Illness score of at least 4 (moderately ill) at
             screening. Subjects may be treated as in- or out-patients. Subjects must give written
             informed consent.

        Exclusion Criteria:

          -  Subjects with other psychiatric, medical or behavioural comorbid disorder that may
             interfere with study conduct or interpretation.

          -  Female of childbearing potential, unless the subject is using a reliable method of
             contraception

          -  Subjects with alcohol or psychoactive-substance dependence not in full remission or
             with significant alcohol or substance abuse in the past 3 months will be excluded.

          -  Laboratory test results outside the range of reference considered by the investigator
             to be clinically significant.

          -  Inability to respect the visit schedule and known intolerance to quetiapine at
             800mg/day.
Clinical trial NCT00070278 (phase 3, status: unknown status)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: cyclophosphamide, epirubicin hydrochloride, gemcitabine hydrochloride, paclitaxel
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed invasive breast cancer

               -  Grade 2 or 3

          -  Tumor size at least 3 cm by ultrasound

          -  No evidence of metastatic disease

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age

          -  Not specified

        Sex

          -  Female

        Menopausal status

          -  Not specified

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Fit to receive study chemotherapy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
Clinical trial NCT01244984 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: fluticasone furoate/gw642444 inhalation powder, fluticasone furoate inhalation powder
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Out patient at least 18 years of age

          -  Both genderds; females of childbearing potential must be willing to use birth control
             method

          -  A diagnosis of asthma at least 6 months prior to Screening

          -  A best FEV1 of at least 50% of the predicted nomal value at Screening

          -  Subjects have been receiving maintanance therapy for asthma, for at least 4 weeks
             prior to Screening

        Exclusion Criteria:

          -  History of life-threating asthma

          -  Respiratory infection or oral candidiasis

          -  Asthma exacerbation within 12 weeks

          -  Concurrent respiratory disease or other disease that would confound study
             participation or affect subject safety

          -  Allergies to study drugs, study drugs7 excipients, medications related to study drugs

          -  Taking another investigational medication or medication prohibited for use during this
             study
Clinical trial NCT01018186 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: fluticasone furoate/gw642444, fluticasone propionate
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of asthma

          -  Reversibility FEV1 of twelve percent or greater and two hundred milliliters and
             greater approximately ten to forty minutes following two to four inhalations of
             albuterol

          -  FEV1 greater than or equal to fifty percent of predicted

          -  Currently using moderate to high dose inhaled corticosteroid therapy

        Exclusion Criteria:

          -  History of life threatening asthma

          -  Respiratory infection or oral candidiasis

          -  Asthma exacerbation

          -  Uncontrolled disease or clinical abnormality

          -  Allergies

          -  Taking another investigational medication or prohibited medication
Clinical trial NCT00485940 (phase 3, status: completed)
Conditions: constipation
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: prucalopride, prucalopride
SMILES: COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1, COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Male and non-pregnant, non breast-feeding female outpatients at least 18 years of age
             (no upper age limit).

          2. History of constipation; the subject reports, ona average,two of fewer spontaneous
             bowel movements per week that result in a feeling of complete evacuation and one or
             more of the following for at least 6 months before the selection visit:

               1. very hard (little balls) and/or hard stools at least a quarter of the stools

               2. sensation of incomplete evacuation following at least a quarter of the stools

               3. straining at defecation at least a quarter of the time. The above criteria are
                  only applicable for spontaneous bowel movements, i.e., not preceded within a
                  period of 24 hours by the intake of a laxative agent or by the use of an enema.

        Subjects who never have spontaneous bowel movements are considered to be constipated and
        are eligible for the trial.

        Exclusion Criteria:

          1. Subjects in whom constipation is thought to be drug-induced, or subjects using any
             disallowed medication.

          2. Subjects suffering from endocrine disorders, metabolic disorders or neurologic
             disorders.

          3. Subjects with a megacolon/megarectum or a diagnosis of pseudo-obstruction.

          4. Constipation as a result of surgery.

          5. Known or suspected organic disorders of the large bowel, i.e. obstruction, carcinoma,
             or inflammatory bowel disease.

          6. Subjects with severe and clinically uncontrolled cardiovascular, liver, or lung
             disease, neurologic or psychiatric disorders (including active alcohol or drug abuse),
             cancer or AIDS, and other gastrointestinal or endocrine disorders.

          7. Subjects with impaired renal function.

          8. Subjects with clinically significant abnormalities of haematology, urinalysis, or
             blood chemistry.

          9. Females of child-bearing potential without adequate contraceptive protection during
             the trial.
Clinical trial NCT01397461 (phase 3, status: completed)
Conditions: impetigo
ICD codes: L01.00, L01.02, L01.03, L01.09, L01.01
Drugs: ozenoxacin placebo, retapamulin 1% ointment, ozenoxacin 1% cream
SMILES: CNC1=NC=C(C=C1C)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1C)C(O)=O, [H][C@]12CC[C@]([H])(C[C@]([H])(C1)SCC(=O)O[C@]1([H])C[C@@](C)(C=C)[C@@]([H])(O)[C@]([H])(C)[C@]34CCC(=O)[C@@]3([H])[C@@]1(C)[C@]([H])(C)CC4)N2C, CNC1=NC=C(C=C1C)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of bullous or non bullous impetigo. The patient has a total
             affected area comprised between 1-100 cm2 with surrounding erythema not extending more
             than 2 cm from the edge of any affected area. In case of multiple affected areas the
             total area will be the sum of each affected area and will not exceed 100 cm2.
             Additionally for patients < 12 years the total area will not exceed a maximum of 2% of
             the body surface area.

          -  Total Skin Infection Rating Scale (SIRS) score of at least 8, including pus/exudate
             score of at least 1

        Exclusion Criteria:

          -  Has a bacterial infection, which in the opinion of the investigator, could not be
             appropriately treated by a topical antibiotic.

          -  Has systemic signs and symptoms of infection (e.g. a fever; defined as an axillary
             temperature over 37.2 °C (99.0 °F)
Clinical trial NCT00645398 (phase 3, status: completed)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: pregabalin, pregabalin, pregabalin, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who met the American College of Rheumatology (ACR) criteria for fibromyalgia
             (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18
             specific tender point sites)

          -  Patients who completed at least 4 pain diaries within the last 7 days and the average
             pain score must have been ≥4, and had a score of ≥40 mm on the Visual Analogue Scale
             (VAS) of the SF-MPQ at screening (Visit 1) and randomization (Visit 2)

        Exclusion Criteria:

          -  Patients with other severe pain that may confound assessment or self-evaluation of the
             pain associated with fibromyalgia

          -  Patients with any inflammatory muscle or rheumatologic disease other than
             fibromyalgia, active infections, or untreated endocrine disorders

          -  Patients with severe depression
Clinical trial NCT00700102 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: chemotherapy, bevacizumab
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, >=18 years of age

          -  Metastatic colorectal cancer and disease progression

          -  Previously treated with first-line chemotherapy plus Avastin

          -  Eastern Cooperative Oncology Group (ECOG) performance status <=2.

        Exclusion Criteria:

          -  Diagnosis of progression of disease more than 3 months after last Avastin
             administration

          -  First-line patients with progression-free survival in first-line of <3 months

          -  Patients receiving less than 3 consecutive months of Avastin in first-line therapy

          -  Past or current history (within the last 2 years prior to treatment start) of other
             malignancies, except for curatively treated basal and squamous cell cancer of the skin
             or in situ cancer of the cervix

          -  Clinically significant cardiovascular disease within 6 months prior to start of study
             treatment

          -  Known central nervous system (CNS) disease, except for treated CNS metastases as
             defined by protocol
Clinical trial NCT00183001 (phase 3, status: completed)
Conditions: osteoporosis, vascular calcification, inflammation
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS, M61.40, M61.411, M61.412, M61.419, M61.431, M61.432, M61.439, H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103
Drugs: vitamin k
SMILES: CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Ambulatory general population

          -  Dietary intake of vitamin K below 120 mcg

        Exclusion Criteria:

          -  Unable to give informed consent

          -  Usual dietary intake of phylloquinone greater than 120 µg/d

          -  Usual dietary calcium intake greater than 1500 mg/d

          -  Usual dietary vitamin D intake greater than 1500 IU

          -  Women less than 5 years postmenopausal

          -  Femoral neck BMD (bone mineral density) at screening that is greater than 1.8 SD above
             or below an age-matched reference mean

          -  24-hour calcium to creatinine ratio exceeding 300 mg/g for women or 350 mg/g for men

          -  Terminal illness

          -  Renal or liver disease requiring treatment

          -  Kidney stone in the past 5 years

          -  Current hyperparathyroidism

          -  Bilateral hip surgery

          -  Treatment with a bisphosphonate, calcitonin, estrogen progestin, androgen, tamoxifen,
             or fluoride (other than dental rinse), or any other treatment for osteoporosis in
             previous 3 months

          -  Warfarin or anticoagulant use in the past 12 months

          -  Nonambulation

          -  Known coronary disease, defined by myocardial infarction or unstable angina

          -  Prior open heart surgery

          -  Atrial fibrillation
Clinical trial NCT00623428 (phase 3, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: peginterferon alfa-2a, ribavirin
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  serological evidence of chronic hepatitis C (CHC);

          -  CHC genotype 2 or 3;

          -  receiving PEGASYS + Copegus according to local standard of care and no rapid viral
             response (RVR);

          -  compensated liver disease.

        Exclusion Criteria:

          -  pegylated interferon, standard interferon or ribavirin therapy at any time prior to
             initiation of current therapy with PEGASYS + Copegus;

          -  coinfection with hepatitis A or B, or human immunodeficiency virus (HIV);

          -  history or other evidence of decompensated liver disease.
Clinical trial NCT00226135 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: lithium or lamotrigine
SMILES: [Li+]
Eligibility criteria:

        Inclusion criteria:

          1. Age above 18

          2. Inclusion is preceded by an affective episode requiring hospitalisation or outpatient
             drug treatment (index episode) which can be a manic episode (ICD-10 research
             criteria), a depressive episode of at least moderate degree (ICD-10 research criteria)
             or a mixed manic state (manic episode with at least additional three ICD-10 depressive
             symptoms except for difficulties with concentration or thinking, agitation or
             dyssomnia). The episode can be with or without psychotic symptoms including
             Schneiderian first-rank symptoms or bizarre delusions as long as the psychotic
             symptoms do not occur outside the affective episode.

          3. No more than 12 months may pass between the onset of the index episode (or admission
             if that is the case)and date of randomisation (in order to ensure a current risk of
             relapse as well as reliable psychopathological information).

          4. Besides the index episode, at least one previous episode must have occurred within the
             last five years which meets the criteria mentioned in point number two above. This
             episode may not necessarily have led to hospitalisation. Two episodes are separated by
             at least two months without significant symptoms or change in polarity (depression to
             mania/mixed mania or vice versa).

          5. At least one manic episode (or mixed manic episode) within the last 5 years.

        Exclusion criteria:

          1. Contraindications to the protocol drugs.

          2. Severe somatic disease, e.g. epilepsy, which may interfere with study treatment or
             effect evaluation.

          3. Pregnancy (or risk of pregnancy).

          4. Subject has prior to randomization received prophylactic treatment with lithium or
             lamotrigine conducted adequately in the sense of sufficient time and dose and ensuring
             compliance, and experienced a definite lack of prophylactic effect

          5. An ICD-10 diagnosis of abuse within the last year with a subsequent risk of protocol
             violation. Therefore, subjects with a secondary abuse can often be included in the
             study.

          6. Anticipated protocol violation for other reasons.

          7. No written informed consent from the subject can be obtained.

          8. The subject has previously been randomised in the study.
Clinical trial NCT00003682 (phase 3, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: doxorubicin hydrochloride, methylprednisolone
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Reason stopped: 
    lack of inclusions
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically proven, symptomatic prostate cancer Appearance or
        aggravation of clinical symptoms with progression of disease Bone pain OR Urethral
        compression OR 20% decrease in performance status Metastatic disease Local-regional or
        distant secondary tumors Documented radiologically or scintigraphically Hormone-refractory
        as defined by progression while on hormone treatment (simple castration or complete
        androgen blockage) Progressive disease No urethral or cervical stenosis Increase of greater
        than 25% prostatic volume on endorectal echography No documentation by PSA increase or
        imagery only Hormone castration verified by testosterone less than 0.5 ng/mL No history of
        CNS metastases

        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 60-100% Life
        expectancy: No specified Hematopoietic: Neutrophil count greater than 1500/mm3 Platelet
        count greater than 100,000/mm3 Hemoglobin greater than 9 g/dL Hepatic: Bilirubin less than
        1.5 times normal Renal: Creatinine less than 1.6 mg/dL Cardiovascular: Ventricular ejection
        fraction at least 50% Other: No contraindication to anthracycline treatment No prior
        primary cancer except basal cell skin cancer

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Arm I: No concurrent chemotherapy Endocrine therapy: At least 1 month since
        prior hormone therapy, including estramustine, except LHRH agonists, which continue Arm I:
        No concurrent estramustine Radiotherapy: At least 3 months since prior strontium 89 No
        concurrent strontium Surgery: See Disease Characteristics
Clinical trial NCT00313209 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: roflumilast, placebo
SMILES: FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  History of COPD for at least 12 months prior to baseline visit

          -  FEV1/FVC ratio (post-bronchodilator) ≤ 70%

          -  FEV1 (post-bronchodilator) between ≥ 40% and ≤ 70% of predicted

        Main Exclusion Criteria:

          -  COPD exacerbation indicated by a treatment with systemic glucocorticosteroids and/or
             antibiotics not stopped at least 4 weeks prior to baseline visit